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In this paper, we provide evidence that anergized NK cells through secreted factors and
direct cell–cell contact have the ability to induce differentiation of healthy dental pulp stem
cells and stem cell of apical papillae as well as transformed oral squamous cancer stem
cell (OSCSC) and Mia-Paca-2, poorly differentiated stem-like pancreatic tumors, resulting
in their resistance to NK cell-mediated cytotoxicity. Induction of NK cell resistance and dif-
ferentiation in the stem cells correlated with the increased expression of CD54, B7H1, and
MHC class I, and mediated by the combination of membrane-bound or secreted IFN-γ and
TNF-α from the NK cells since antibodies to both cytokines and not each one alone were
able to inhibit differentiation or resistance to NK cells. Similarly, antibodies to both TNF-α
and IFN-γ were required to prevent NK-mediated inhibition of cell growth, and restored the
numbers of the stem cells to the levels obtained when stem cells were cultured in the
absence of anergized NK cells. Interestingly, the effect of anti-IFN-γ antibody in the absence
of anti-TNF-α antibody was more dominant for the prevention of increase in surface receptor
expression since its addition abrogated the increase in CD54, B7H1, and MHC class I sur-
face expression. Antibodies to CD54 or LFA-1 was unable to inhibit differentiation whereas
antibodies to MHC class I but not B7H1 increased cytotoxicity of well-differentiated oral
squamous carcinoma cells as well as OSCSCs differentiated by the IL-2+ anti-CD16 mAb-
treated NK cells whereas it inhibited the cytotoxicity of NK cells against OSCSCs.Thus, NK
cells may inhibit the progression of cancer by killing and/or differentiation of cancer stem
cells, which severely halt cancer growth, invasion, and metastasis.
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INTRODUCTION
Recent advances in our understanding of anti-tumor immune
responses and cancer biology have revealed a complex dynamic
interaction between the immune effectors and the tumor cells.
Effectors of the immune system are known to shape tumor cells
(immuno-editing) and select for cancers with reduced immuno-
genicity and enhanced capacity to actively induce immuno-
suppression. However, the same effector mechanisms are likely
responsible for the selection of healthy stem cells with enhanced
capacity to induce immunosuppression for the ultimate goal of
wound healing, tissue regeneration, and cessation of inflamma-
tion. Much work has been done to identify strategies by which
tumor cells evade the immune system. Altered expression of MHC
class I molecules which modulate the function of T and NK cells
are one of the examples of such mechanism. In addition, tumor
cells induce T and NK cell apoptosis, block lymphocyte homing
and activation, and dampen macrophage and dendritic cell func-
tion by releasing immunosuppressive factors such as Fas, VEGF,
IL-6, IL-10, TNF-α, GM-CSF, and IL-1β. Many factors responsible
for the suppression of NK cell cytotoxicity in humans have been
previously identified (1–6). It has been shown that freshly isolated
tumor infiltrating NK cells are not cytotoxic to autologous tumors.
Moreover, NK and T cells obtained from the peripheral blood of
patients with cancer have significantly reduced cytotoxic activity
(7–14). In addition, NK cell cytotoxicity is suppressed after their
interaction with stem cells (15–17).
We have previously shown that K562, an NK-sensitive tumor,
causes loss of NK cell cytotoxicity while increasing IFN-γ secre-
tion by the NK cells, and induces cell death in a small subset
of NK cells (18, 19). On the other hand, NK-resistant tumors
such as RAJI cells do not induce loss of NK cell cytotoxicity nor
IFN-γ secretion (18, 19). Furthermore, following NK cell cul-
tures with sensitive tumor-target cells overnight, the target binding
NK cells undergo phenotypic and functional changes expressing
CD16−CD56+/dim/−CD69+ phenotype (18, 19). Significant
down-modulation of CD16 receptor expression and decreased NK
cell cytotoxic function were also seen in cancer patients including
those who suffer from oral and ovarian cancers (20, 21). In addi-
tion, down-regulation of CD16 surface receptors on NK cells was
also observed when NK cells were treated with CA125 isolated
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from ovarian tumor cells (22). The decrease in CD16 surface
receptors was accompanied by a major decrease in NK cell killing
activity against K562 tumor cells (22). These observations sug-
gested that CD16 receptors may play an important role in target
cell-induced loss of NK cell cytotoxicity. Furthermore, we have
previously shown that triggering of CD16 on NK cells was found
to result in down-modulation of CD16 receptors and in a great
loss of cytotoxicity and augmented secretion of IFN-γ, which we
have previously coined as “split anergy” (18, 19, 23–27). Loss of
cytotoxicity in NK cells was significantly increased when NK cells
were either treated with anti-MHC class I antibody (25) or treated
with F(ab)′2 fragment of anti-CD16 mAb (25, 27).
Progress has been made in identification of the upstream mech-
anisms, which control the expression of immunosuppressive fac-
tors in tumor cells. Two key control elements, NFκB and STAT3
were shown to regulate coordinately the production of multiple
tumor-derived immunosuppressive molecules and play a pivotal
role in tumor cell immune suppression.
The significance and exact mechanisms by which NFκB nuclear
function in oral tumors modulate and shape the function of key
interacting immune effectors is starting to unravel. We have previ-
ously shown that differentiated primary oral epithelial tumors,
unlike their cancer initiating cells, demonstrate higher nuclear
NFκB activity and secrete significant levels of cytokines and
chemokines, and are resistant to NK cell-mediated cytotoxic-
ity (28, 29). Moreover, inhibition of NFκB in differentiated oral
squamous carcinoma cells (OSCCs), or in non-tumorigenic oral
keratinocytes (HOK-16B) leads to a significant increase in NK
cell-mediated cytotoxicity and secretion of IFN-γ (30, 31). In addi-
tion, targeted inhibition of NFκB in skin epithelial cells resulted
in the induction of auto-immunity and inflammation (32). Also,
blocking of NFκB function in both the intestinal epithelial cells
and myeloid cells was previously shown to result in a significant
decrease in size and numbers of the tumor cells (33).
Our previous studies indicated that the stage of maturation
and differentiation of healthy untransformed stem cells, as well as
transformed tumorigenic cancer stem cells, is predictive of their
sensitivity to NK cell lysis. In this regard, we have shown that oral
squamous cancer stem cells (OSCSCs), which are stem-like oral
tumors, are significantly more susceptible to NK cell-mediated
cytotoxicity; whereas, their differentiated counterpart OSCCs is
significantly more resistant (29). In addition, hESCs and hiPSCs, as
well as a number of other healthy normal stem cells such as hMSCs
and hDPSCs, were found to be significantly more susceptible to
NK cell-mediated cytotoxicity than their differentiated counter-
parts (29). Based on these results, we proposed that NK cells may
play a significant role in differentiation of the cells by providing
critical signals via secreted cytokines as well as direct cell–cell con-
tact. In addition, we have shown previously that CD14+HLADR−
monocytes can condition NK cells to lose cytotoxicity and secrete
inflammatory cytokines (34–38). The signals received from the
stem cells or monocytes alter the phenotype of NK cells and cause
NK cells to lose cytotoxicity and change into cytokine-producing
cells. These alterations in NK cell effector function are thought
to ultimately aid in driving differentiation of a minor popula-
tion of surviving, healthy, as well as transformed stem cells. In
this paper, we demonstrate that anergized NK cells contribute
to differentiation and subsequent resistance of stem cells to NK
cell-mediated cytotoxicity through cell–cell contact and secreted
cytokines.
MATERIALS AND METHODS
CELL LINES, REAGENTS, AND ANTIBODIES
RPMI 1640 supplemented with 10% fetal bovine serum (FBS)
(Gemini Bio-Products, CA, USA) was used for the cultures of
human NK cells and monocytes. OSCCs and stem-like OSCSCs
were isolated from oral cancer patient tongue tumors at UCLA,
and cultured in RPMI 1640 supplemented with 10% FBS (Gemini
Bio-Products, CA, USA), 1.4% antibiotic antimycotic, 1% sodium
pyruvate, 1.4% non-essential amino acids, 1% l-glutamine, 0.2%
gentamicin (Gemini Bio-Products, CA, USA), and 0.15% sodium
bicarbonate (Fisher Scientific, PA, USA). Mia-Paca-2 (MP2) were
cultured in DMEM with 10% FBS and 1% penicillin and strep-
tomycin (Gemini Bio-Products, CA, USA). Dental pulp stem
cells (DPSCs) and stem cell of apical papillae (SCAP) were cul-
tured in DMEM complete medium supplemented with 2% FBS
and 1% penicillin and streptomycin (Gemini Bio-Products, CA,
USA). To induce differentiation of DPSCs, they were cultured
with DMEM in the presence of ascorbic acid (50µg/ml), Na-
β-glycerophosphate (10 mM) (Sigma Aldrich, MO, USA), and
dexamethasone (10−8 M).
Recombinant IL-2 was obtained from NIH-BRB. Recombinant
TNF-α and IFN-γ were obtained from BioLegend (San Diego,
CA, USA). The anti-B7H1 was a generous gift from Dr. Liping
Chen. Antibodies to CD16, CD54, and LFA-1 were purchased
from BioLegend (San Diego, CA, USA). Anti-MHC class I were
prepared in our laboratory and 1:100 dilution was found to be
the optimal concentration to use. PE – anti-CD26, anti-CD54,
anti-CD44, anti-B7H1, anti-CD166, anti-CD326, and anti-CD338
were obtained from BioLegend (San Diego, CA, USA). Antibod-
ies to TNF-α and IFN-γ were prepared in our laboratory and
1:100 dilution was found to be the optimal concentration to use.
The human NK and monocyte purification kits were obtained
from Stem Cell Technologies (Vancouver, BC, Canada). Cisplatin
was obtained through Ronald Reagan Pharmacy at UCLA. Mon-
ensin was purchased through BioLegend (San Diego, CA, USA).
Propidium iodide (PI) is purchased from Sigma Aldrich (Buffalo,
NY, USA).
PURIFICATION OF NK CELLS AND MONOCYTES
PBMCs from healthy donors were isolated as described before (19).
Briefly, peripheral blood lymphocytes were obtained after Ficoll–
hypaque centrifugation and purified NK cells were negatively
selected by using an NK cell isolation kit (Stem Cell Technologies,
Vancouver, BC, Canada). The purity of NK cell population was
found to be>90% based on flow cytometric analysis of anti-CD16
antibody-stained cells. The levels of contaminating CD3+ T cells
remained low, at 2.4± 1%, similar to that obtained by the non-
specific staining using isotype control antibody throughout the
experimental procedures. The adherent subpopulation of PBMCs
was detached from the tissue culture plates and the total popula-
tion of monocytes was purified using isolation kit obtained from
Stem Cell Technologies (Vancouver, BC, Canada). Greater than
95% purity was achieved based on flow cytometric analysis of
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CD14 and CD16 antibody-stained monocytes. Written informed
consents approved by UCLA Institutional Review Board (IRB)
were obtained from the blood donors and all the procedures were
approved by the UCLA IRB.
ELISA AND MULTIPLEX CYTOKINE ARRAY KIT
Single ELISAs were performed as described previously (19). Flu-
orokine MAP cytokine multiplex kits were purchased from R&D
Systems (Minneapolis, MN, USA) and the procedures were con-
ducted as suggested by the manufacturer. To analyze and obtain the
cytokine concentration, a standard curve was generated by either
two or threefold dilution of recombinant cytokines provided by
the manufacturer. Analysis was performed using the Star Station
software.
SURFACE STAINING AND CELL DEATH ASSAYS
Staining was performed by labeling the cells with antibodies or PI
as described previously (19, 24, 39).
51Cr RELEASE CYTOTOXICITY ASSAY
The 51Cr release assay was performed as described previously (31).
Briefly, different numbers of purified NK cells were incubated with
51Cr-labeled tumor-target cells. After a 4-h incubation period, the
supernatants were harvested from each sample and counted for
released radioactivity using the gamma counter. The percentage
specific cytotoxicity was calculated as follows:
% Cytotoxicity = Experimental cpm− spontaneous cpm
Total cpm− spontaneous cpm
LU 30/106 is calculated by using the inverse of the number of
effector cells needed to lyse 30% of tumor-target cells× 100.
STEM CELL DIFFERENTIATION WITH NK CELL SUPERNATANT
Human NK cells were purified from healthy donor’s PBMCs as
described above. NK cells were left untreated or treated with anti-
CD16 mAb (3µg/ml), IL-2 (1000 units/ml), or a combination of
IL-2 (1000 units/ml) and anti-CD16 mAb (3µg/ml) for 18–24 h
before the supernatants were removed and used in differentia-
tion experiments. The amounts of IFN-γ produced by activated
NK cells were assessed with IFN-γ ELISA (BioLegend, CA, USA).
Differentiation of OSCSCs was conducted with gradual daily addi-
tion of increasing amounts of NK cell supernatant. On average,
a total of 1500 pg of IFN-γ containing supernatants obtained
from IL-2+ anti-CD16 mAb-treated NK cells was added for 5 days
to induce differentiation and resistance of OSCSCs to NK cell-
mediated cytotoxicity. DPSCs and SCAP cells required on average
a total of 3600 pg of IFN-γ containing supernatants obtained from
IL-2+ anti-CD16 mAb-treated NK cells during a 7-day treatment,
whereas MP2 tumors required a total of 7000 pg of IFN-γ contain-
ing supernatants from IL-2+ anti-CD16 mAb-treated NK cells
for 7 days to promote differentiation and resistance to NK cell-
mediated cytotoxicity. Afterward, target cells were rinsed with 1×
PBS, detached, and used for experiments.
STEM CELL DIFFERENTIATION WITH 2% PARAFORMALDEHYDE-FIXED
NK CELLS
Human NK cells were purified as described above. NK cells were
left untreated or treated with anti-CD16 mAb (3µg/ml), IL-2
(1000 units/ml), or a combination of IL-2 (1000 units/ml) and
anti-CD16 mAb (3µg/ml) for 18–24 h. Afterward, supernatants
were removed and the NK cells were fixed with freshly prepared
2% paraformaldehyde for 15 min. NK cells were then rinsed three
times with 1× PBS and added to tumor cultures. Differentiation
of OSCSCs was conducted on average in 5 days with daily and
gradual addition of increasing amounts of fixed NK cells. Dur-
ing the differentiation process of OSCSCs, NK cells were added to
tumor cells at an effector to target ratio of 0.75–1 for 5 days. For
the differentiation of DPSCs, an effector to target ratio of 2:1 was
added to culture for 7 days. After the treatment period, NK cells
were removed from the tumors and the target cells were used for
experiments.
TREATMENT OF NK CELLS WITH MONENSIN
NK cells were purified from healthy donor’s PBMCs as described
above. NK cells were left untreated or treated with IL-2
(1000 units/ml) and anti-CD16 mAb (3µg/ml) with or without
monensin (1:1300) for 24 h as per manufacturer’s recommenda-
tion. Afterward, the supernatants were harvested from NK cells
and the amounts of IFN-γ produced were measured with IFN-γ
ELISA (BioLegend, CA, USA). NK cells were then fixed with freshly
prepared 2% paraformaldehyde for 15 min and then washed three
times with 1× PBS. Thereafter, fixed NK cells were added to
OSCSCs at an effector to target ratio of 0.75–1. After 5 days of
treatment, NK cells were removed from culture and OSCSCs were
used for experiments.
STATISTICAL ANALYSIS
An unpaired, two-tailed Student t -test was performed for the sta-
tistical analysis. One-way ANOVA with a Bonferroni post-test was
used to compare the different groups.
RESULTS
RESISTANCE OF DIFFERENTIATED OSCCs BUT NOT STEM-LIKE OSCSCs
AND DPSCs TO NK CELL-MEDIATED CYTOTOXICITY; LOSS OF NK CELL
CYTOTOXICITY AND GAIN IN SECRETION OF IFN-γ AFTER NK CELL
RECEPTOR SIGNALING
NK cells were left untreated or treated with anti-CD16 antibody
and/or IL-2 for 18–24 h before they were used with OSCSCs or
their differentiated counterparts OSCCs. As shown previously and
in here, using time-lapse microscopic analysis, NK cells mediated
much higher lysis of stem-like OSCSCs when compared to dif-
ferentiated OSCCs (Figure 1A). We had previously characterized
stem-like OSCSCs and differentiated OSCCs based on their surface
expression (29), and in this report we extended the characteriza-
tion of stem-like OSCSCs to include other stem cell markers of
CD26, CD326 (EpCam), CD166, and CD338 (Figures 1B,C). As
shown in Figures 1B,C, OSCSCs expressed significantly higher
amounts of CD26, CD326, and CD338 and lower amounts of
CD166 similar to those reported previously (40–43). In agreement
with the increased expression of CD338 (Figure 1C), OSCSCs
were significantly more resistant to cisplatin (Figure 1D) and
paclitaxel (manuscript in preparation) when compared to differ-
entiated counterparts. In accordance to the data obtained with
the time-lapse microscopy, both untreated and IL-2-treated NK
cells mediated higher lysis of OSCSCs when compared to OSCCs
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FIGURE 1 | Resistance of differentiated DPSCs and OSCCs but not
stem-like OSCSCs or DPSCs to untreated, IL-2-treated, and
IL-2+anti-CD16-treated NK cell cytotoxicity; loss of NK cell
cytotoxicity and gain in secretion of IFN-γ after NK cell receptor
signaling. OSCCs or OSCSCs were seeded at 1×105 cells/well in 24-well
plate for 24 h prior to the addition of highly purified NK cells pre-treated
with IL-2 (1000 units/ml) for 24 h. NK cells were added to tumor cells at 2:1
effector to target ratio. At time 0 when NK cells were added to the tumor
culture, a final concentration of 10µg/ml of propidium iodide (PI) was also
added. The cells were then subsequently tracked for over 72 h using
time-lapse microscopy with Nikon Eclipse Ti-E inverted microscope fitted
with a culture chamber to provide cells with a stable temperature of 37°C
with 5% CO2. An image was taken every 15 min and a representation is
shown at day 1, day 1½, and day 3. OSCSCs but not OSCCs which are
lysed take up PI and appear orange in the time-lapse (A). The surface
expression of CD26, CD44, CD166, and CD326 on OSCCs and OSCSCs
were assessed with flow cytometric analysis after staining with the
respective PE-conjugated antibodies. Isotype control antibodies were used
as control. The numbers on the right hand corner are the percentages and
the mean channel fluorescence intensities for each histogram (B). The
surface expression of CD338 on OSCCs and OSCSCs was assessed by
flow cytometric analysis after staining with PE-conjugated CD338 (right
graphs in the histogram). Isotype control antibodies were used as control
(left graphs in the histograms) (C). OSCCs and OSCSCs were left untreated
or treated with 10–80µg/ml of cisplatin for 18 h, after which the tumor cells
were washed with 1× PBS, detached, and stained with propidium iodide
(PI) and percent cell death was determined using flow cytometric analysis
(D). NK cells were left untreated or treated with IL-2 (1000 units/ml),
anti-CD16 mAb (3µg/ml), or a combination of IL-2 (1000 units/ml) and
anti-CD16 mAb (3µg/ml) for 18 h before they were added to 51Cr-labeled
OSCSCs and OSCCs (E) or undifferentiated and differentiated DPSCs (G).
(Continued)
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FIGURE 1 | Continued
NK cell-mediated cytotoxicity was determined using a standard 4 h 51Cr
release assay and the lytic units 30/106 cells were determined using inverse
number of NK cells required to lyse 30% of the target cells×100. NK cells
were treated as described in (E) and each NK sample was either cultured in
the absence or presence of OSCSCs and OSCCs (F) or undifferentiated and
differentiated DPSCs (H) at an NK cell to target cell ratio of 0.5:1. After an
overnight incubation, the supernatant was removed from the co-cultures and
the levels of IFN-γ secretion were determined using specific ELISAs. One of
minimum three representative experiments is shown in each of (B–H).
in a 4-h 51Cr release assay (P < 0.05), and IL-2-treated NK cells
secreted significant levels of IFN-γ in co-culture with OSCSCs
when compared to OSCCs (Figures 1E,F). Anti-CD16 mAb treat-
ment inhibited NK cell cytotoxicity against both OSCSCs and
OSCCs (P < 0.05), however, it did not induce any appreciable
secretion of IFN-γ (Figures 1E,F). The addition of the combina-
tion of IL-2 and anti-CD16 mAb treatment although inhibited NK
cell cytotoxicity significantly against OSCSCs and OSCCs when
compared to IL-2-activated NK cells alone (P < 0.05), it induced
higher release of IFN-γ when cultured in the presence and absence
of OSCSCs (Figures 1E,F). The levels of IFN-γ secretion remained
much less in the co-cultures of IL-2 and/or anti-CD16 mAb-
treated NK cells with OSCCs when compared to those cultured
with OSCSCs (P < 0.05) correlating with the decreased cyto-
toxicity by IL-2-treated NK cells against OSCCs (Figures 1E,F).
Therefore, anti-CD16 mAb in combination with IL-2 induced split
anergy in NK cells resulting in a great loss of cytotoxicity but sig-
nificant gain in secretion of IFN-γ against oral stem-like tumors
(Figures 1E,F).
To determine whether similar results to those demonstrated
above can be obtained by healthy untransformed primary stem
cells and their differentiated counterparts, we performed the
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FIGURE 2 | Monocytes induce split anergy in NK cells resulting in a
significant loss of NK cell cytotoxicity against OSCSCs and DPSCs and
increased secretion of IFN-γ by the NK cells. NK cells were purified from
healthy donors and left untreated or treated with IL-2 (1000 units/ml),
anti-CD16 mAb (3µg/ml), or the combination of IL-2 (1000 units/ml) and
anti-CD16 mAb (3µg/ml) in the presence or absence of autologous
monocytes (1:1 ratio of NK:monocytes) for 24 h, after which they were
washed and added to 51Cr-labeled OSCSCs in a 4-h chromium release assay.
Percent cytotoxicity was obtained at different effector to target ratio, and the
lytic units 30/106 cells were determined using inverse number of NK cells
required to lyse 30% of the tumor cells×100 (A). NK cells were treated as
described in Figure 2A and either cultured in the absence or presence of
OSCSCs. After an overnight incubation, supernatants were removed from
co-cultures and the levels of IFN-γ secretion were determined using specific
ELISAs (B). Highly purified NK cells were left untreated or treated as
described in Figure 2A. After 1, 4, 6, and 8 days post-treatment,
supernatants were removed from NK cell cultures and the levels of IFN-γ
(Continued)
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FIGURE 2 | Continued
(C) release were determined using specific ELISAs. NK cells were purified
from healthy donors and left untreated or treated with IL-2 (1000 units/ml),
anti-CD16 mAb (3µg/ml), or the combination of IL-2 (1000 units/ml) and
anti-CD16 mAb (3µg/ml) in the presence or absence of autologous and
allogeneic monocytes (1:1 ratio of NK:monocytes) for 24 h, after which they
were washed and added to 51Cr-labeled autologous and allogeneic DPSCs in a
4-h chromium release assay (D). Percent cytotoxicity was obtained at
different effector to target ratio, and the lytic units 30/106 cells were
determined using inverse number of NK cells required to lyse 30% of the
tumor cells×100. NK cells were treated as described in Figure 2D and either
cultured in the absence or presence of autologous and allogeneic DPSCs
(NK:DPSC of 0.2:1). After an overnight incubation, supernatants were
removed from the co-cultures and the levels of IFN-γ secretion were
determined using specific ELISAs (E). One of minimum three representative
experiments is shown in each of (A–E).
following experiments. NK cells were treated as described in
Figure 1E before they were added to 51Cr-labeled DPSCs and
their differentiated counterparts. As shown in Figure 1G, IL-2-
treated NK cells mediated much higher lysis of undifferentiated
DPSCs when compared to differentiated DPSCs (P < 0.05). Anti-
CD16 mAb treatment inhibited NK cell cytotoxicity against both
undifferentiated and differentiated DPSCs (P < 0.05), however, it
did not induce any appreciable secretion of IFN-γ (Figure 1H).
The addition of the combination of IL-2 and anti-CD16 mAb
treatment although inhibited NK cell cytotoxicity against undiffer-
entiated and differentiated DPSCs significantly, when compared to
IL-2-activated NK cells alone (P < 0.05), it induced higher release
of IFN-γ when cultured in the presence and absence of DPSCs
(Figure 1H). The levels of IFN-γ secretion remained much less
in the co-cultures of IL-2 or IL-2 and anti-CD16 mAb-treated
NK cells with differentiated DPSCs when compared to those cul-
tured with undifferentiated DPSCs (P < 0.05) correlating with the
decreased cytotoxicity by IL-treated NK cells against differenti-
ated DPSCs (Figures 1G,H). The levels of IFN-γ secretion in the
co-cultures of undifferentiated DPSCs with IL-2 alone or IL-2
in combination with anti-CD16 mAb-treated NK cells plateaued
(Figure 1H).
MONOCYTES INDUCE SPLIT ANERGY IN NK CELLS RESULTING IN A
SIGNIFICANT LOSS OF NK CELL CYTOTOXICITY AGAINST OSCSCs AND
DPSCs AND INCREASED SECRETION OF IFN-γ BY THE ANERGIZED NK
CELLS
Monocytes were purified from PBMCs and irradiated at 20 Gy.
OSCSCs were co-cultured with allogeneic irradiated monocytes
before they were labeled with 51Cr and used in the cytotoxic-
ity assays against NK cells. NK cells were treated as indicated in
Figure 1A and they were used in the cytotoxicity assays against
OSCSCs and DPSCs. The addition of irradiated monocytes to
OSCSCs significantly protected the OSCSCs (Figure 2A) from
NK cell-mediated cytotoxicity (P < 0.05). Significant inhibition
of NK cell cytotoxicity by monocytes could be observed against
untreated and IL-2-treated NK samples (P < 0.05) (Figure 2A).
Purified irradiated monocytes were also co-cultured with OSCSCs
and untreated or IL-2 and/or anti-CD16 mAb pre-treated NK cells
were added before the supernatants were removed and subjected
to specific ELISAs for IFN-γ (Figure 2B). Irradiated monocytes
cultured with OSCSCs increased secretion of IFN-γ substantially
when added to IL-2 or IL-2 and anti-CD16 antibody-treated NK
cells. Since monocytes alone or monocytes cultured with OSCSCs
did not have any effect on IFN-γ secretion in all the experiments
tested, we did not include them in Figure 2 (data not shown). In
addition, when secretion of IFN-γ were determined in 8 days, IL-
2+ anti-CD16 mAb-treated NK cells continuously secreted higher
levels of IFN-γ only in the presence of monocytes at days 4 and
6, whereas IL-2+ anti-CD16 mAb-treated NK cells in the absence
of monocytes had very low levels of secretion at days 4 and 6
(P < 0.05) (Figure 2C). No significant secretion could be observed
in any of the samples at day 8 (Figure 2C). At day 1, IL-2+ anti-
CD16 mAb-treated NK cells secreted high levels of IFN-γ and the
levels increased in the presence of monocytes (Figure 2C). Mono-
cytes in the absence of NK cells were unable to secrete IFN-γ (data
not shown). Overall, these experiments indicated that monocytes
induce split anergy in NK cells resulting in protection of OSC-
SCs from NK cell-mediated lysis while substantially increasing the
secretion of IFN-γ.
Similar to OSCSCs, DPSCs were co-cultured with and with-
out irradiated allogeneic and autologous monocytes before they
were labeled with 51Cr and used in the cytotoxicity assays against
allogeneic and autologous NK cells. NK cells were treated as indi-
cated in Figure 1 before they were used in the cytotoxicity assays
against DPSCs. As shown in Figure 2D, untreated, IL-2-treated,
and IL-2+ anti-CD16 mAb-treated autologous NK cells lysed
DPSCs to similar extents to those obtained with allogeneic NK
cells. Addition of irradiated monocytes to DPSCs inhibited NK
cell-mediated cytotoxicity in all treated NK samples and the lev-
els of decrease were similar between autologous and allogeneic
NK cells (Figure 2D). Significant inhibition of NK cell cytotoxic-
ity could be obtained by treating autologous and allogeneic NK
cells with IL-2 and anti-CD16 mAb when compared to IL-2-
treated NK cells. In contrast, IL-2 and anti-CD16 mAb-treated NK
cells secreted large amounts of IFN-γ and the levels substantially
increased when added to monocyte-treated DPSCs (Figure 2E).
Similar levels of IFN-γ secretion was obtained by both autologous
and allogeneic NK cells when these cells were treated with IL-2
alone or IL-2+ anti-CD16 mAb in the presence and absence of
DPSCs (Figure 2E).
SUPERNATANTS FROM THE COMBINATION OF IL-2 AND anti-CD16
mAb-TREATED NK CELLS INDUCED RESISTANCE OF OSCSCs AND
DPSCs TO NK CELL-MEDIATED CYTOTOXICITY AND INCREASED
DIFFERENTIATION ANTIGENS ON THE SURFACE OF OSCSCs
NK cells were treated as described in Figure 1A before their super-
natants were removed and added to OSCSCs as described in the
Section “Materials and Methods.” Treatment of OSCSCs with IL-
2+ anti-CD16 mAb-treated NK cell supernatants decreased NK
cell-mediated cytotoxicity significantly by untreated and IL-2-
treated NK cells (P < 0.05) (Figure 3A). Resistance of OSCSCs
to NK cell-mediated cytotoxicity could also be observed after their
treatment with IL-2 and much less with anti-CD16 mAb-treated
NK supernatants, but the levels of NK resistance were signifi-
cantly less when compared to those induced by IL-2+ anti-CD16
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FIGURE 3 | Supernatants and paraformaldehyde-fixed NK cells
treated with IL-2 in combination with anti-CD16 mAb with and
without monocytes increased resistance of OSCSCs and DPSCs to
NK cell-mediated cytotoxicity. NK cells were purified from healthy
donors and left untreated or treated with IL-2 (1000 units/ml), anti-CD16
mAb (3µg/ml), or the combination of IL-2 (1000 units/ml) and anti-CD16
mAb (3µg/ml) in the presence or absence of autologous monocytes (1:1
ratio of NK:monocytes) for 24 h, after which the same amounts of
supernatants from different treatments of NK cells were removed and
added to OSCSCs for a period of 5 days (A) or DPSCs for a period of
7 days (B). NK supernatant-treated OSCSCs or DPSCs were then washed
with 1× PBS, detached and labeled with 51Cr, and used in the cytotoxicity
assay against freshly isolated NK cells. Untreated or IL-2-treated
(Continued)
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FIGURE 3 | Continued
(1000 units/ml) NK cells were used to assess cytotoxicity against NK
supernatant-treated target cells using a standard 4 h 51Cr release assay.
Percent cytotoxicity was determined at different effector to target ratio,
and the lytic units 30/106 cells were determined using inverse number of
NK cells required to lyse 30% of the tumor cells×100. NK cells were
purified from healthy donors and left untreated or treated with IL-2
(1000 units/ml), anti-CD16 mAb (3µg/ml), or the combination of IL-2
(1000 units/ml) and anti-CD16 mAb (3µg/ml) in the presence or absence
of monocytes (1:1 ratio of NK:monocytes) for 24 h. Treated NK samples
were then washed and fixed with 2% paraformaldehyde for 15 min before
they were either added to OSCSCs at 0.75:1 for 5 days (C) or DPSCs at
2:1 for 7 days (D). The fixed NK cells were then completely removed from
OSCSCs and DPSCs and the target cell sensitivity to NK cell-mediated
lysis were determined using a standard 4 h 51Cr release assay using
freshly isolated and untreated or IL-2-treated (1000 units/ml) NK cells.
Removal of fixed NK cells from stem cell cultures were assessed using
microscopic observation. Percent cytotoxicity was determined at different
effector to target ratio, and the lytic units 30/106 cells were determined
using inverse number of NK cells required to lyse 30% of the tumor
cells×100. One of minimum three representative experiments is shown
in each of (A–D).
mAb-treated NK cell supernatants (P < 0.05) correlating with the
degree of differentiation based on the surface receptors (please
see below). Supernatants harvested from irradiated monocytes
with IL-2+ anti-CD16-treated NK cells and added to OSCSCs
resulted in a further increase in the resistance of OSCSCs to
NK cell-mediated cytotoxicity (Figure 3A). Supernatants from
irradiated monocytes and IL-2-treated NK cells were also able
to induce resistance of OSCSCs (P < 0.05) but the levels of
resistance were less when compared to that induced by super-
natants obtained from the combination of IL-2 and anti-CD16
mAb-treated NK cells in the presence of irradiated monocytes
(Figure 3A).
Similarly, treatment of DPSCs with IL-2+ anti-CD16 mAb-
treated NK cell supernatants significantly decreased cytotoxicity
mediated by IL-2-treated NK cells (P < 0.05) (Figure 3B). Addi-
tion of supernatants removed from the co-cultures of IL-2-treated
NK cells with monocytes to DPSCs increased resistance of these
cells against IL-2-treated NK cells, however, the highest resis-
tance was observed in DPSCs treated with supernatants removed
from cultures of monocytes with the combination of IL-2 and
anti-CD16 mAb-treated NK cells (Figure 3B).
ADDITION OF PARAFORMALDEHYDE-FIXED IL-2+ anti-CD16
mAb-TREATED NK CELLS WITH ANDWITHOUT IRRADIATED
MONOCYTES TO OSCSCs AND AUTOLOGOUS DPSCs-MEDIATED
RESISTANCE OF OSCSCs AND DPSCs AGAINST NK CELL-MEDIATED
CYTOTOXICITY
Similar to the treatment of OSCSCs with the NK cell super-
natants, OSCSCs became resistant to NK cell-mediated cytotox-
icity after their co-culture with IL-2+ anti-CD16 mAb-treated
paraformaldehyde-fixed NK cells (P < 0.05) when compared to
the addition of untreated or anti-CD16 mAb-treated or IL-2-
treated fixed NK cells (Figure 3C). The complete removal of fixed
NK cells from the OSCSCs prior to the cytotoxicity assays were
determined by microscopic assessment. Co-cultures of IL-2 and
IL-2+ anti-CD16 mAb-treated NK cells with monocytes before
their fixation and addition to OSCSCs increased resistance of
these cells against untreated and IL-2-treated NK cells and the
highest resistance was observed in OSCSCs which were cultured
with monocytes and the combination of IL-2 and anti-CD16
mAb-treated NK cells although monocytes cultured with IL-2-
treated NK cells were also able to induce resistance in OSCSCs
(Figure 3C).
Similarly, cultures of DPSCs with paraformaldehyde-fixed
autologous IL-2+ anti-CD16 mAb pre-treated NK cells decreased
NK cell-mediated cytotoxicity by untreated and IL-2-treated NK
cells significantly (P < 0.05) (Figure 3D). Cultures of irradiated
monocytes with the IL-2-treated NK cells before their addition to
DPSCs increased resistance of these cells against IL-2-treated NK
cells moderately, however, the highest resistance was observed in
DPSCs which were cultured with monocytes and the combination
of IL-2 and anti-CD16 mAb-treated NK cells (Figure 3D).
INDUCTION OF NK RESISTANCE IN OSCSCs CORRELATED WITH THE
INCREASED EXPRESSION OF CD54, B7H1, MHC CLASS I, AND
DECREASED EXPRESSION OF CD44
We then compared NK cell resistance induced by the NK cell
supernatant in OSCSCs to expression of key cell surface recep-
tors. Among many surface receptors tested, CD44, CD54, B7H1,
and MHC class I expression was found to correlate significantly
with the differentiation and resistance of OSCSCs to NK cell-
mediated cytotoxicity (Figure 4A). As shown in Figure 4A, the
levels of CD54, MHC class I, and B7H1 increased substantially on
OSCSCs whereas the levels of CD44 decreased in the presence of
IL-2+ anti-CD16 mAb-treated NK cell supernatants (Figure 4A).
Treatment of OSCSCs with IL-2 alone treated NK supernatants
modulated the above mentioned surface receptors moderately,
and the levels were less when compared to those modulated by
the supernatants obtained from IL-2+ anti-CD16 mAb-treated
NK cells (Figure 4A). As expected, supernatants obtained from
the monocytes with IL-2+ anti-CD16 mAb-treated NK cells up-
regulated both CD54 and MHC class I substantially more when
compared to either monocytes alone or IL-2+ anti-CD16 mAb-
treated NK cells in the absence of monocytes (Figure 4B). Since
the highest increase in resistance to NK cell cytotoxicity and aug-
mented expression of CD54, B7H1, and MHC class I were found in
the presence of the treatment of OSCSCs with supernatants from
IL-2+ anti-CD16 mAb-treated NK cells; i.e., anergized NK cells,
we used this treatment hereafter for the remaining of the studies.
To determine growth dynamics of OSCSCs after treatment
with the NK supernatants, the number of attached and detached
OSCSCs were counted after treatment with the supernatants by
microscopic evaluation and the levels of cell death were deter-
mined by staining with PI followed by flow cytometric analy-
sis. As shown in Figure 4C, there was a decrease in the num-
bers of OSCSCs after their treatment with IL-2 and anti-CD16
mAb-treated NK cell supernatants when compared to untreated
OSCSCs or those treated with untreated NK cell supernatants
(Figure 4C). However, the highest decrease was observed when
OSCSCs were cultured with the supernatants obtained from the
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FIGURE 4 | Induction of resistance to NK cell-mediated cytotoxicity and
inhibition of growth in OSCSCs correlated with the increased
expression of CD54, B7H1, MHC class I, and decreased expression of
CD44 on OSCSCs treated with supernatants from IL-2+anti-CD16
mAb-treated NK cells with and without monocytes. NK cells were
purified from healthy donors and left untreated or treated with IL-2
(1000 units/ml), anti-CD16 mAb (3µg/ml), or the combination of IL-2
(1000 units/ml) and anti-CD16 mAb (3µg/ml) for 24 h. Thereafter, the same
amounts of supernatants from different treatments of NK cells were
removed and added to OSCSCs for 5 days. OSCSCs were then washed, and
the expression of CD54, CD44, B7H1, and MHC class I were assessed after
staining with the PE-conjugated antibodies using flow cytometry (A). NK
cells were purified from healthy donors and left untreated or treated with
IL-2 (1000 units/ml), anti-CD16 mAb (3µg/ml), or the combination of IL-2
(1000 units/ml) and anti-CD16 mAb (3µg/ml) in the presence or absence of
autologous monocytes (1:1 ratio of NK:monocytes) for 24 h. Thereafter, the
same amounts of supernatants from different treatments of NK cells were
removed and added to OSCSCs. After 5 days of incubation with the NK cell
supernatants, OSCSCs were washed with 1× PBS, and the expression of
CD54 and MHC-1 were assessed after staining with the PE-conjugated
antibodies using flow cytometry (B). Isotype control antibodies were used
as controls. The numbers on the right hand corner are the percentages and
the mean channel fluorescence intensities for each histogram.
(Continued)
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FIGURE 4 | Continued
At the end of the incubation of OSCSCs with NK cell supernatants,
OSCSCs which were remained attached to the plate and those which
detached during the incubation period were collected separately, and the
number of cells (C) and their viability (D) were assessed using microscopy
and propidium iodide staining followed by flow cytometric analysis,
respectively. One of minimum three representative experiments is shown
in each of (A–D).
combination of IL-2+ anti-CD16 mAb-treated NK cells with
monocytes (Figure 4C). Interestingly, monocytes alone increased
growth of the OSCSCs when compared to untreated OSCSCs
(Figure 4C). When the numbers of detached OSCSCs were deter-
mined, no significant differences could be observed in those
treated with NK supernatants alone and the highest increase was
seen when OSCSCs were cultured with the supernatants obtained
from the combination of IL-2+ anti-CD16 mAb-treated NK cells
with monocytes (Figure 4C). Similarly, 12% increase in cell death
could be seen when OSCSCs were treated with the combination of
IL-2+ anti-CD16 mAb-treated NK cells with monocytes, whereas
no cell death in attached OSCSCs could be observed when they
were treated with the IL-2+ anti-CD16 mAb-treated NK cells in
the absence of monocytes (Figure 4D). Although slight increases
in cell death of detached OSCSCs were seen when these cells were
treated with IL-2+ anti-CD16 mAb-treated NK cell supernatants
(10%), the levels increased substantially in detached cells when
OSCSCs were treated with the supernatants from the combina-
tion of IL-2+ anti-CD16 mAb-treated NK cells and monocytes
(Figure 4D).
INDUCTION OF RESISTANCE IN OSCSCs TO NK CELL-MEDIATED
CYTOTOXICITY BY ANERGIZED NK CELLS IS MEDIATED BY THE
COMBINATION OF IFN-γ AND TNF-α AND NOT EACH CYTOKINE ALONE
To examine the mechanisms by which OSCSCs become resistant
by anergized NK cells, we determined NK cell-mediated cyto-
toxicity when OSCSCs were treated with supernatants of NK
cells treated with anti-CD16 mAb and IL-2 in the presence and
absence of each of IFN-γ and TNF-α antibodies alone or their
combination. As shown in Figures 5A–C, the addition of each
of the IFN-γ and TNF-α antibody alone had a slight inhibitory
effect on the induction of resistance of OSCSCs by the super-
natants of NK cells treated with IL-2+ anti-CD16 mAb, however,
the combination of anti-IFN-γ and anti-TNF-α abrogated the
resistance of treated OSCSCs completely (Figures 5A–C). The
inhibition of OSCSCs resistance to NK cell-mediated cytotox-
icity by the combination of anti-IFN-γ and anti-TNF-α anti-
bodies could be observed when either untreated (Figure 5A),
IL-2-treated (Figure 5B), or IL-2+ anti-CD16 mAb-treated NK
cells (Figure 5C) were used to assess cytotoxicity. Addition of iso-
type control antibodies to IL-2+ anti-CD16 mAb-treated NK cell
supernatants did not change the resistance of OSCSCs to NK cell-
mediated cytotoxicity (Figure 5). Resistance of OSCSCs induced
by supernatants from IL-2+ anti-CD16 mAb-treated NK cells cor-
related with increased expression of CD54, B7H1, and MHC class
I as shown above and the addition of a combination of anti-
TNF-α and anti-IFN-γ antibodies prevented the up-regulation
of these receptors (Figure 5D). The effect of anti-IFN-γ mAb in
the absence of anti-TNF-α antibody, however, was more dominant
for surface receptor modulation than cytotoxicity or cell growth
(please see below) since its addition abrogated the increase in sur-
face receptor expression substantially (Figure 5D). In addition,
the rate of OSCSC cell growth was decreased when supernatants
obtained from IL-2+ anti-CD16-treated NK cells were added,
and this decrease was completely inhibited in the presence of the
combination of anti-IFN-γ and anti-TNF-α antibodies and not
each antibody alone (Figure 5E). Moreover, when the numbers
(Figure 5E) and viability (Figure 5F) of OSCSCs attached or
detached from the culture plates were determined after the addi-
tion of supernatants from the IL-2+ anti-CD16 mAb-treated NK
cells, decreased growth rate with equal numbers of attached and
detached OSCSCs were seen and the addition of the combina-
tion of anti-TNF-α and anti-IFN-γ restored the growth rate and
eliminated the increase in detached OSCSCs (Figures 5E,F). No
or slight decreases in the viability of attached OSCSCs could be
seen after their treatment with the supernatants from IL-2+ anti-
CD16 mAb-treated NK cells. In contrast, significant increases
in cell death of detached OSCSCs could be seen (Figure 5F).
Interestingly, treatment of OSCSCs with supernatants from IL-
2+ anti-CD16 mAb-treated NK cells in the presence of anti-
IFN-γ alone demonstrated reduced death of detached OSCSCs
(Figure 5F).
Similar results to those obtained with OSCSCs were also
observed when undifferentiated or stem-like Mia-Paca-2 (MP2)
pancreatic tumors or SCAP were used to treat with the super-
natants of NK cells treated with IL-2+ anti-CD16 mAb in the
presence and absence of anti-TNF-α and/or anti-IFN-γ (Figure
S1 in Supplementary Material).
INDUCTION OF DIFFERENTIATION AND RESISTANCE TO NK
CELL-MEDIATED CYTOTOXICITY OF OSCSCs BY ANERGIZED
PARAFORMALDEHYDE-FIXED NK CELLS IS MEDIATED BY THE
COMBINATION OF IFN-γ AND TNF-α AND NOT EACH CYTOKINE ALONE
Similar to the data shown above, the addition of each of the
IFN-γ and TNF-α antibody alone had a slight inhibitory effect
on the resistance of OSCSCs induced by the paraformaldehyde-
fixed NK cells treated with IL-2+ anti-CD16 mAb, however,
the combination of anti-IFN-γ and anti-TNF-α abrogated the
resistance of treated OSCSCs completely (Figure 6A). IL-2 and
IL-2+ anti-CD16 mAb pre-treated and paraformaldehyde-fixed
NK cells neither were able to mediate cytotoxicity (Figure 6B)
nor secrete IFN-γ (Figure 6C) or TNF-α (data not show) after
fixation, and they expressed membrane-bound TNF-α and IFN-
γ when assessed by flow cytometric analysis using antibodies to
TNF-α and IFN-γ (Figure 6D). The inhibition of OSCSCs resis-
tance to NK cell-mediated cytotoxicity by the combination of
anti-IFN-γ and anti-TNF-α antibodies could be observed when
IL-2-treated NK cells were used to assess cytotoxicity (Figure 6A).
Resistance of OSCSCs by IL-2+ anti-CD16 mAb-treated fixed NK
cells correlated with increased expression of CD54, B7H1, and
MHC class I and the addition of a combination of anti-TNF-
α and anti-IFN-γ antibodies prevented up-regulation of these
receptors (Figure 6E). Similarly, the effect of anti-IFN-γ mAb
in the absence of anti-TNF-α antibody was more dominant for
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FIGURE 5 | Induction of resistance of OSCSCs to NK cell-mediated
cytotoxicity and inhibition of growth in OSCSCs by IL-2+anti-CD16
mAb-treated NK cells is mediated by the combination of IFN-γ and
TNF-α and not each cytokine alone. Highly purified NK cells were
treated with the combination of IL-2 (1000 units/ml) and anti-CD16 mAb
(3µg/ml) for 24 h, after which supernatant was removed and added to
OSCSCs in the presence and absence of anti-TNF-α (1:100) and/or
anti-IFN-γ (1:100) or isotype control antibodies for a period of 5 days. The
cytotoxicity against untreated and NK supernatant-treated OSCSCs in the
presence of antibodies to untreated NK cells (A), IL-2-treated NK cells
(B), or IL-2 and anti-CD16 mAb-treated NK cells (C) were assessed using
a standard 4 h 51Cr release assay. Percent cytotoxicity was obtained at
different effector to target ratio, and the lytic units 30/106 cells were
determined using inverse number of NK cells required to lyse 30% of the
tumor cells×100. The surface expression of CD54, CD44, B7H1,
(Continued)
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FIGURE 5 | Continued
and MHC class I on untreated, anti-TNF-α (1:100) and anti-IFN-γ (1:100)
in the absence of NK supernatant, IL-2+ anti-CD16 mAb treated NK
supernatants in the presence and absence of anti-TNF-α and/or
anti-IFN-γ as shown in the figure were assessed were assessed after
PE-conjugated antibody staining using flow cytometric analysis.
Isotype control antibodies were used as controls. The numbers on the
right hand corner are the percentages and the mean channel
fluorescence intensities in each histogram (D). At the end of the
incubation of OSCSCs with NK cell supernatants, OSCSCs which
were remained attached to the plate and those which detached during
the incubation period were collected separately, and the number of
cells (E) and their viability (F) were assessed using microscopy, and
propidium iodide staining followed by flow cytometric analysis,
respectively. One of minimum three representative experiments is
shown in each of (A–F).
surface receptor expression than cytotoxicity or cell growth since
its addition abrogated the increase in surface receptor expres-
sion substantially (Figures 6A,E,F). The rate of OSCSC cell
growth was decreased when IL-2+ anti-CD16-treated fixed NK
cells were added, and this decrease was completely inhibited in
the presence of the combination of anti-IFN-γ and anti-TNF-
α antibodies and not each antibody alone (Figure 6F). More-
over, when the numbers (Figure 6F) and viability (Figure 6G)
of attached OSCSCs from the cultured plates were determined
after the addition of IL-2+ anti-CD16 mAb-treated fixed NK
cells, decreased growth rate of OSCSCs were seen and the addi-
tion of the combination of anti-TNF-α and anti-IFN-γ restored
the growth rate (Figure 6F). No or slight decreases in the viabil-
ity of attached OSCSCs could be seen after their treatment with
the IL-2+ anti-CD16 mAb-treated fixed NK cells (Figure 6G).
Although, increased numbers of detached OSCSCs could be
observed in the presence of IL-2+ anti-CD16 mAb-treated fixed
NK cells, accurate numbers of detached OSCSCs and their viabil-
ity could not be established because of contamination with fixed
NK cells.
Similar results to those obtained with OSCSCs were also
observed when undifferentiated or stem-like MP2 or SCAP were
used to treat with the IL-2+ anti-CD16 mAb-treated fixed NK
cells in the presence and absence of anti-TNF-α and/or anti-IFN-γ
(data not shown).
To determine whether monensin-treated fixed anergized NK
cells lose the ability to induce resistance of OSCSCs against NK
cell-mediated cytotoxicity, first we established that treatment of
NK cells with IL-2+ anti-CD16 mAb in the presence of mon-
ensin blocked substantially the release of IFN-γ in the super-
natants (Figure 6H). Addition of monensin in combination
with IL-2+ anti-CD16-treated and fixed NK cells to OSCSCs
inhibited resistance of OSCSC against untreated (Figure 6I),
IL-2 (Figure 6J), or IL-2+ anti-CD16 mAb-treated NK cells
(Figure 6K) when compared to IL-2+ anti-CD16 mAb-treated
fixed NK cells in the absence of monensin treatment. Treatment
of NK cells with the combination of IL-2+ anti-CD16 mAb and
monensin inhibited the increase in CD54 and MHC class I expres-
sion on OSCSCs when compared to those induced by IL-2+ anti-
CD16 mAb-treated and fixed NK cells (Figure 6L). No cell death
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FIGURE 6 | Induction of differentiation, inhibition of cell growth, and
resistance to NK cell-mediated cytotoxicity in OSCSCs induced by
IL-2+anti-CD16 mAb-treated and paraformaldehyde-fixed NK cells is
mediated by the combination of IFN-γ andTNF-α and not each cytokine
alone. Highly purified NK cells were left untreated or treated with the
combination of IL-2 (1000 units/ml) and anti-CD16 mAb (3µg/ml) for 24 h, after
which the NK cells were fixed with 2% paraformaldehyde and added to
OSCSCs (0.75:1 NK:OSCSC ratio) in the presence and absence of anti-TNF-α
(1:100) and/or anti-IFN-γ (1:100) or isotype control antibodies for a period of
5 days. The media containing the fixed NK cells were removed and extensively
washed from each treated OSCSCs and the cytotoxicity against OSCSCs
were assessed using freshly isolated untreated NK cells or those treated with
IL-2 using a standard 4 h 51Cr release assay. The complete removal of fixed NK
cells from OSCSCs was determined by microscopy. Percent cytotoxicity was
obtained at different effector to target ratio, and the lytic units 30/106 cells
were determined using inverse number of NK cells required to lyse 30% of
the tumor cells×100 (A). The lack of cytotoxic function of 2%
paraformaldehyde-fixed untreated and IL-2-treated NK cells were assessed
against OSCSCs and OSCCs. NK cells were left untreated or treated with IL-2
for 24 h before they were fixed with 2% paraformaldehyde (B). NK cells were
purified from healthy donor and left untreated or treated with IL-2
(1000 units/ml) and the combination of IL-2 (1000 units/ml) and anti-CD16 mAb
(3µg/ml). After an overnight treatment, NK cells were fixed with freshly
prepared 2% paraformaldehyde and washed twice with 1× PBS. After 24 h
post fixation, supernatants were then collected and the levels of IFN-γ were
measured with specific ELISA (C). NK cells purified from healthy donors were
left untreated or treated with a combination of IL-2 (1000 units/ml) and
anti-CD16 mAb (3µg/ml) for 24 h, after which the NK cells were washed
extensively and stained with PE-conjugated anti-TNF-α mAb followed by flow
cytometric analysis. IFN-γ expression was assessed using purified mouse
anti-human IFN-γ antibody followed by PE-conjugated goat anti-mouse IgG.
Isotype control antibodies were used as controls. The numbers on the right
hand corner are percentage positive for each histogram. The histogram
overlay for the anti-TNF-α or anti-IFN-γ stained untreated (left) and
IL-2+ anti-CD16 mAb-treated NK cells (right) are also shown in this figure.
(Continued)
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FIGURE 6 | Continued
(D) The surface expression of CD54, CD44, B7H1, and MHC class I on
untreated and fixed NK-treated OSCSCs as described above were assessed
after PE-conjugated antibody staining followed by flow cytometric analysis.
Isotype control antibodies were used as controls. The numbers on the right
hand corner are the percentages and the mean channel fluorescence
intensities for each histogram (E). At the end of the incubation of OSCSCs
with fixed NK cells, OSCSCs which were remained attached to the plate were
collected, and the number of cells (F) and their viability (G) were assessed
using microscopy, and propidium iodide staining followed by flow cytometric
analysis, respectively. Highly purified NK cells were left untreated or treated
with the combination of IL-2 (1000 units/ml) and anti-CD16 mAb (3µg/ml) in
the presence and absence of monensin (1:1300) for 24 h, after which each
sample of NK cells were extensively washed and fixed with 2%
paraformaldehyde and added to OSCSCs (0.75:1 NK:OSCSC) for a period of
5 days. Inhibition of IFN-γ release in monensin-treated NK cells before fixation
with 2% paraformaldehyde were assessed by ELISA (H).
(Continued)
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FIGURE 6 | Continued
The results were compared to OSCSCs in the absence of fixed NK cells. The
media containing the fixed NK cells were removed and extensively washed
from each treated OSCSCs and the cytotoxicity against each condition of
OSCSCs were assessed using freshly isolated untreated NK cells (I), those
treated with IL-2 (J) or treated with the combination of IL-2+ anti-CD16 mAb
(K) using a standard 4 h 51Cr release assay. The complete removal of fixed NK
cells from OSCSCs was determined by microscopy. Differentiated OSCCs
were used as control for the differentiation of OSCSCs. Percent cytotoxicity
was obtained at different effector to target ratio, and the lytic units 30/106
cells were determined using inverse number of NK cells required to lyse 30%
of the tumor cells×100. The surface expression of CD54, CD44, and MHC
class I on untreated and fixed NK-treated OSCSCs as described above were
assessed after PE-conjugated antibody staining followed by flow cytometric
analysis. Isotype control antibodies were used as controls. The numbers on
the right hand corner are the percentages and the mean channel fluorescence
intensities for each histogram (L). At the end of the incubation of OSCSCs
with fixed NK cells, the media containing the fixed NK samples were removed
from OSCSCs and the viability of the cells were assessed using propidium
iodide staining followed by flow cytometric analysis (M). One of minimum
three representative experiments is shown in each of (A–M).
(Continued)
could be observed in attached OSCSCs with any of treatments
(Figure 6M).
COMBINATION OF rTNF-α AND rIFN-γ INDUCE DIFFERENTIATION AND
RESISTANCE OF OSCSCs TO NK CELL-MEDIATED CYTOTOXICITY
Oral squamous cancer stem cells were treated with rTNF-α
and/or rIFN-γ in the presence and absence of anti-TNF-α mAb
or anti-IFN-γ antiserum. As shown in Figure 7A, addition of
rTNF-α to OSCSCs was able to induce some resistance against
IL-2-treated NK cell-mediated cytotoxicity and this resistance
was moderately blocked by the addition of anti-TNF-α anti-
body. rIFN-γ-treated OSCSCs were significantly more resistant
to IL-2-treated NK cells when compared to rTNF-α-treated OSC-
SCs and the addition of anti-IFN-γ blocked resistance (P < 0.05)
(Figure 7A). Since the addition of rIFN-γ had reduced the NK
cytotoxicity substantially, further decrease with the combination
of rTNF-α and rIFN-γ was difficult to demonstrate in this exper-
iment (Figure 7A). No significant cell death could be observed
in all treated samples at the concentrations of rTNF-α and rIFN-
γ tested (Figure 7B). However, at the higher concentration of
rTNF-α and rIFN-γ, when the combination of rTNF-α and rIFN-
γ were used, an increase in the numbers of detached OSCSCs
and cell death in both the attached and detached OSCSCs but
not MP2 or SCAP could be observed (data not shown). Both
rTNF-α and rIFN-γ were able to upregulate CD54 and MHC
class I expression significantly, however, only rIFN-γ was able to
upregulate B7H1 expression moderately on OSCSCs (Figure 7C).
Addition of a combination of rTNF-α and rIFN-γ synergistically
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FIGURE 6 | Continued
induced the expression of CD54 and B7H1, but not MHC class
I (Figure 7C). Similar results to those obtained with OSCSCs
were also obtained with SCAP and DPSCs. RTNF-α induced
resistance to NK cell-mediated cytotoxicity less than rIFN-γ and
the combination of rIFN-γ and rTNF-α further reduced IL-2-
mediated cytotoxicity (Figure S2A in Supplementary Material).
Unexpectedly, the level of CD44 was augmented by the treat-
ment of rTNF-α and rIFN-γ and their combination, and the
addition of anti-TNF-α and anti-IFN-γ antibodies blocked the
increase substantially on DPSCs whereas it inhibited the increase
in CD54, B7H1, and MHC class I expression by the combi-
nation of rTNF-α and rIFN-γ (Figure S2B in Supplementary
Material).
ANTIBODIES TO CD54 OR LFA-1 WAS UNABLE TO INHIBIT
DIFFERENTIATION IN OSCSCs
Addition of antibodies to CD54 (Figure 8A) or its ligand LFA-
1 (Figure 8B) in the initiation of differentiation of OSCSCs with
supernatants from IL-2+ anti-CD16 mAb-treated NK cells for the
duration of differentiation and their subsequent removal by exten-
sive washing before labeling of OSCSCs with 51Cr and addition to
freshly isolated IL-2-treated NK cells did not reverse differentia-
tion in supernatant differentiated OSCSCs, however, it did inhibit
cytotoxicity moderately in IL-2+ anti-CD16 mAb supernatant
differentiated OSCSCs. In addition, unlike the effect of antibodies
to TNF-α and IFN-γ, addition of anti-CD54 or anti-LFA-1 did
not restore the numbers of OSCSCs to the levels seen with the
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FIGURE 7 | Combination of rTNF-α and rIFN-γ induce differentiation and
resistance of OSCSCs and SCAP to NK cell-mediated cytotoxicity.
OSCSCs (A) were left untreated or treated with recombinant human TNF-α
(2 ng/ml), recombinant human IFN-γ (5 units/mL), or the combination of
human TNF-α (2 ng/ml) and recombinant human IFN-γ (5 units/ml) in the
presence or absence of antibodies against TNF-α (1:100) and/or IFN-γ (1:100)
for 24 h. Afterwards, the cells were detached from the tissue culture plates
and labeled with 51Cr and used in a standard 4 h chromium release assay
against untreated and IL-2-treated (1000 units/ml) NK cells. Pre-treatment of
NK cells with IL-2 were carried out for 18–24 h. Percent cytotoxicity was
determined at different effector to target ratio, and the lytic units 30/106 cells
were determined using inverse number of NK cells required to lyse 30% of
the tumor cells ×100. OSCSCs were treated as described in Figure 2A and
their viability was assessed using propidium iodide staining followed by the
flow cytometric analysis (B). Surface expressions of CD54, CD44, B7H1, and
MHC-1 on OSCSCs (C) treated as described in Figure 2A were determined
using staining with PE-conjugated antibodies followed by flow cytometric
analysis. Isotype control antibodies were used as controls. The numbers on
the right hand corner are the percentages and the mean channel fluorescence
intensities in each histogram. One of minimum three representative
experiments is shown in each of (A–C).
(Continued)
untreated OSCSCs as seen in Figure 5E (data not shown). More-
over, the addition of CD54 and LFA-1 antibodies to untreated
OSCSCs and those treated with untreated NK supernatants for
the duration of differentiation and extensive washing to remove
remaining antibodies before 51Cr labeling and culture with freshly
isolated NK cells in 51Cr release assay did not change NK cell
cytotoxicity (Figures 8A,B).
ANTIBODIES TO B7H1 AND MHC CLASS I DID NOT CHANGE OR
INCREASED CYTOTOXICITY OF OSCSCs DIFFERENTIATED BY
IL-2+ anti-CD16 mAb-TREATED NK SUPERNATANTS RESPECTIVELY
In contrast to anti-CD54 or anti-LFA-1, which were added at
the initiation of differentiation and were present for the entire
differentiation period, antibodies to B7H1 and MHC class I
were added after the differentiation in the cultures of NK cells
with the 51Cr-labeled differentiated targets only for 4 h to assess
their significance in cytotoxicity and not differentiation since
B7H1 and MHC class I were shown previously to regulate
cytotoxicity of NK cells and were found to be elevated on the
surface of OSCSCs differentiated with the IL-2+ anti-CD16 mAb-
treated NK supernatants. As shown in Figure 9A, the addition
of B7H1 antibody even though moderately increased cytotoxi-
city when added to untreated OSCSCs, it had no effect when
added to IL-2+ anti-CD16 mAb NK supernatant differentiated
OSCSCs even though the surface expression of B7H1 was sig-
nificantly elevated on differentiated OSCSCs. In contrast, the
addition of anti-MHC class I significantly increased cytotoxicity
when added to IL-2+ anti-CD16 mAb NK supernatant differen-
tiated OSCSCs, whereas it had inhibitory effect when added to
untreated OSCSCs (Figure 9B). Addition of anti-MHC class I to
well-differentiated OSCCs also increased cytotoxicity significantly
(Figure 9B).
DISCUSSION
In this paper, we provide evidence that conditioned or anergized
NK cells have the ability to induce resistance and differentia-
tion of stem cells through secreted factors and direct cell–cell
contact. Both secreted and membrane-bound IFN-γ and TNF-α
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FIGURE 7 | Continued
were found to be important for the induction of resistance of OSC-
SCs and DPSCs to NK cell-mediated cytotoxicity, and inhibition
of cell growth and proliferation, since combination of antibod-
ies to TNF-α and IFN-γ and not each one alone was able to
restore susceptibility to NK-mediated cytotoxicity and increase
the number of tumor cells. On the other hand, IFN-γ appears
to be more dominant in increasing cell surface receptors on dif-
ferentiated OSCSCs and DPSCs since the addition of anti-IFN-γ
antibody was able to block the expression of CD54, MHC class
I, and B7H1 largely, even though the addition of the combina-
tion of rIFN-γ and rTNF-α was found to induce CD54, B7H1,
and MHC class I expression synergistically. IL-2 and anti-CD16
mAb-activated fixed NK cells expressed membrane-bound TNF-α
and IFN-γ and mediated differentiation and resistance of OSC-
SCs and DPSCs. Indeed, both soluble and immobilized IFN-γ was
shown to mediate neuronal differentiation in a dose-dependent
manner (44), and membrane-bound IFN-γ has previously been
shown to protect mice from metastasis of Lewis lung carcinomas
to a comparable extent to that mediated by the secreted cytokines
(45). In addition, membrane-bound TNF-α confers protection
against mycobacterial infection (46). These studies underscore
the significance of both secreted and membrane-bound forms
of TNF-α and IFN-γ in tumor therapy and infections. More-
over, the addition of monensin to IL-2+ anti-CD16 mAb pre-
treated fixed NK cells was also able to prevent differentiation, and
increase the numbers, viability, and susceptibility of stem cells to
NK cell-mediated cytotoxicity in the presence of lower expres-
sion of CD54, MHC class I, and B7H1 surface receptors. These
studies indicated that both membrane-bound as well as secreted
forms of TNF-α and IFN-γ are important in differentiation of
stem cells.
When the extent of resistance to NK cell-mediated cytotoxi-
city, cell growth, attachment to culture plates, and viability were
determined in OSCSCs, MP2, and DPSCs after differentiation with
the supernatants or fixed NK cells treated with IL-2+ anti-CD16
mAb, distinct cell signatures in respect to the outcome of differen-
tiation were obtained for each cell type. In addition, the amount
of supernatants used, and the length of treatment time were
two important factors influencing the outcome of differentiation.
While OSCSCs were sensitive to the differentiation effect of NK
cell supernatants and exhibited detachment and cell death at rel-
atively lower amounts of supernatant treatment, and in shorter
period of treatment time, MP2, SCAP, and DPSCs were signifi-
cantly more resistant, and they neither detached nor underwent
cell death in the detached population at higher amounts of NK
supernatants and in longer period of treatment. These differences
could be due to the levels of TNF-α and IFN-γ receptor expres-
sion on each cell type and is the subject of our future studies. In
addition, such differences may be the basis for why certain tumors
are better controlled by the NK cells than the others, and pro-
vide the rationale for designing effective strategies to eliminate
tumors. In agreement, differential effects of IFN-γ and TNF-
α in either causing resistance in tumors or sensitizing them to
NK cell-mediated cytotoxicity has also been reported previously
(47–49).
Since CD54 was strongly elevated during differentiation, we
aimed at understanding its role in differentiation. Addition of anti-
CD54 or anti-LFA-1 antibodies at the initiation of differentiation
of OSCSCs with IL-2+ anti-CD16 mAb-treated NK supernatants,
did not change differentiation of OSCSCs since no restoration of
cell number could be observed (data not shown), and their addi-
tion were moderately inhibitory for the cytotoxicity of NK cells in
IL-2+ anti-CD16 mAb supernatant differentiated OSCSCs sug-
gesting that cell contact through CD54 and LFA-1 may not be
important for the differentiation of OSCSCs by the NK super-
natants. In addition, both B7H1 and MHC class I are shown to
regulate cytotoxicity of NK cells and are elevated on the surface
of NK differentiated OSCSCs. Addition of antibodies to B7H1 did
not increase cytotoxicity of NK cells against differentiated OSC-
SCs even though the surface expression of B7H1 was significantly
elevated on differentiated OSCSCs. In contrast, addition of anti-
body to MHC class I significantly elevated cytotoxicity of NK cells
against NK differentiated OSCSCs and this correlated with signif-
icant augmentation of MHC class I on NK differentiated OSCSCs.
Similarly, the addition of anti-MHC class I antibody to the co-
cultures of NK cells with differentiated primary OSCCs, which
naturally express high surface MHC class I expression, mediated
increased cytotoxicity by the NK cells. In contrast, addition of
antibodies to MHC class I in the co-cultures of NK cells with
stem-like OSCSCs was inhibitory for NK cell cytotoxicity. This
inhibition could be due to the effect of anti-MHC class I anti-
body on NK cells and not on the tumor cells since we have
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FIGURE 8 | Antibodies to CD54 or LFA-1 was unable to reverse
differentiation but inhibited moderately the cytotoxicity of NKs against
differentiated OSCSCs. Highly purified NK cells were left untreated or
treated with the combination of IL-2 (1000 units/ml) and anti-CD16 mAb
(3µg/ml) for 24 h, after which the same amounts of supernatants were
removed and added to the OSCSCs in the presence and absence of anti-CD54
mAb (10µg/ml) (A) and anti-LFA-1 (1:100) (B) for 5 days.Treated OSCSCs were
then washed extensively and used in a standard 4 h 51Cr release assay against
IL-2-activated (1000 units/ml) NK cells. Pre-treatment of NK cells with IL-2
were carried out for 18–24 h. Percent cytotoxicity was determined at different
effector to target ratio, and the lytic units 30/106 cells were determined using
inverse number of NK cells required to lyse 30% of the tumor cells ×100.
previously shown that the addition of anti-MHC class I antibody
to CD16 mAb-activated NK cells mediated significant inhibition
of NK cell cytotoxicity (25). Whether increase in NK cell cytotox-
icity against differentiated tumors by anti-MHC class I is due to
ADCC or blocking of inhibitory ligands on NK cells awaits future
investigation.
It is likely that other immune effectors such as T cells and NKT
cells may also contribute to the pool of IFN-γ and TNF-α when
they are activated, and thus they may be important for driving
differentiation of tumors. In this regard, CD4+ Th1 cells may play
a crucial role. Future studies should be able to establish the signifi-
cance of other cell types in differentiation and resistance of tumor
cells.
Our results suggest two very important functions for the NK
cells. One potential function of NK cells is to limit the number of
stem cells, and second to support differentiation of the stem cells
and their progeny. In respect to the oral squamous cell carcinomas
since the majority of immune effectors are found at the connective
tissue area (Figure 10) (34, 36–38, 50), it is likely that NK cells may
first encounter and interact with either the other immune effectors
or the effectors of connective tissue such as fibroblasts. However,
there is also the possibility that NK cells may first encounter the
basal epithelial stem cells in which case by eliminating the stem
cells, they too can become anergized (Figure 10). By eliminating
a subset of stem cells or after their interaction with other immune
inflammatory cells or effectors of connective tissue, NK cells could
then be in a position to support differentiation of remaining stem
cells since they will be conditioned to lose cytotoxicity and induce
cytokine and growth factor secretion. It is interesting to note that
all of the immune effectors isolated from oral gingival tissues of
healthy as well as diseased gingiva have CD69+ phenotype, with
the exception that the numbers of immune effectors are much
less in the healthy oral gingival tissues when compared to diseased
tissues (34, 36–38, 50) (manuscript in preparation). In addition,
lack of significant infiltration of NK cells in the tumor nest and
the localization of NK cells in the immune-rich compartment,
which surrounds the tumor in other tumor types, also provides
the rationale and the means for the induction of split anergy in NK
cells primarily by other immune effectors in the tumor microen-
vironment (50). Such mechanisms of NK cell conditioning by the
other immune effectors such as myeloid-derived suppressor cells
(MDSCs) explain why the cytotoxic function of NK cells are greatly
reduced in the tumor microenvironment as well as in circulating
NK cells.
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FIGURE 9 | Antibodies to MHC class I increased cytotoxicity of OSCSCs
differentiated by IL-2+anti-CD16 mAb-treated NK supernatants, whereas
antibodies to B7H1 did not change cytotoxicity. OSCSCs were treated
with supernatants harvested from untreated or IL-2+ anti-CD16 mAb-treated
NK cells for 5 days. Treatment of NK cells with the combination of
IL-2+ anti-CD16 mAb were carried out for 18–24 h before the supernatants
were removed and added to OSCSCs. Thereafter, treated OSCSCs were
washed and labeled with 51Cr and used in the cytotoxicity assay in the
presence and absence of anti-B7H1 (5µg/ml) before their addition to NK cells.
Percent cytotoxicity was determined at different effector to target ratio, and
the lytic units 30/106 cells were determined using inverse number of NK cells
required to lyse 30% of the tumor cells ×100 (A). OSCSCs were left
untreated or treated with the supernatants prepared from the IL-2+ anti-CD16
mAb-treated NK cells for 5 days before they were washed, 51Cr-labeled, and
treated with either isotype control antibody or anti-MHC class I antibody
(1:100) for 10 min prior to their use in the cytotoxicity assay against IL-2-treated
(1000 units/ml) NK cells. OSCCs were also 51Cr-labeled and treated with and
without isotype control or anti-MHC class I (1:100) antibodies before they
were used in the cytotoxicity assay against IL-2-treated NK cells. To prepare
NK cell supernatant for the treatment of OSCSCs, NK cells were treated with
the combination of IL-2 (1000 units/ml) and anti-CD16 mAb (3µg/ml) for
18–24 h before the supernatants were harvested and added to OSCSCs. The
treatment of IL-2 (1000 units/ml) was also carried out for 18–24 h before their
use in the cytotoxicity assay. Percent cytotoxicity was determined at different
effector to target ratio, and the lytic units 30/106 cells were determined using
inverse number of NK cells required to lyse 30% of the tumor cells ×100 (B).
There should be two distinct strategies to eliminate tumors,
one which targets stem cells and the other which targets differenti-
ated cells. Since cancer stem cells are found to be more resistant to
chemotherapeutic drugs but sensitive to NK cell-mediated killing
while differentiated oral tumors are more resistant to NK cell-
mediated killing but relatively more sensitive to chemotherapeu-
tic drugs (Figure 1), combination therapy should be considered
for the elimination of both undifferentiated and differentiated
tumors. In addition, since a great majority of patient NK cells have
modified their phenotype to support differentiation of the cells,
they may not be effective in eliminating cancer stem cells. There-
fore, these patients may benefit from repeated allogeneic NK cell
transplantation for elimination of cancer stem cells. In this regard,
depletion of NK anergizing effectors such as monocytes in the
tumor microenvironment which condition NK cells to lose cyto-
toxicity, via radiation or chemotherapeutic drugs before allogeneic
NK cell transplantation should in theory provide such strategy
for targeting the cancer stem cells by the NK cells. However,
this strategy may also halt or decrease the ability of NK cells to
drive optimal differentiation of the tumors and tilt the balance
toward a more inflammatory tumor microenvironment which
may run the risk of fueling the growth and expansion of more
cancer stem cells. Indeed, NK supernatant differentiated tumors
were unable to trigger secretion of cytokines and chemokines,
providing a less inflammatory tumor microenvironment which
may limit the growth and expansion of tumor cells (manuscript
submitted).
Alternatively, a strong tumor differentiating microenvironment
may be induced by the balanced release and membrane expression
of key cytokines by the NK cells anergized with effectors such as
monocytes or healthy stem cells in hope that most if not all of
the newly arising cancer stem cells are induced to differentiate
in order to become less aggressive. The benefit of such approach
will be the ability of chemotherapeutic drugs to target the differ-
entiated tumors in addition to the lack of differentiated tumors
to metastasize (data not shown). Indeed, our recent in vivo data
indicated that cancer stem cells have the ability to grow faster and
metastasize, whereas the differentiated tumors grew slower and
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FIGURE 10 | Hypothetical model of induction of anergized NK cells by
immune inflammatory cells and by the effectors of connective tissue to
support differentiation of non-transformed stem cells and cancer stem
cells resulting in their resistance to NK cell-mediated cytotoxicity. NK cell
anergy in tumor microenvironment, as well as in non-transformed immune
inflammatory microenvironment, is shown. Significant infiltration of immune
effectors right beneath the epithelial layer can be seen in a connective tissue
area where immune inflammatory cells are likely to anergize NK cells to lose
cytotoxicity and gain the ability to secrete cytokines, a term which we
previously coined “split anergy” in NK cells, and to support differentiation of
the basal epithelial layer containing stem cells. NK cells are likely to encounter
and interact with other immune effectors such as monocytes/macrophages or
other myeloid-derived suppressor cells (MDSCs), or with connective
tissue-associated fibroblasts (CAF), in order to be conditioned to form
anergized/regulatory NK (NKreg) cells. NK cells may also directly interact with
stem cells at the base of the epithelial layer, in which case by eliminating their
bound stem cells, they can become conditioned to support differentiation of
other stem cells. NK cell-differentiated epithelial cells will no longer be killed
or induce cytokine secretion by the NK cells, resulting in the resolution of
inflammation.
remained localized for a long period of time without metastasiz-
ing (manuscript in preparation). It is possible that the successful
cancer therapy may lie between a balance in the two abovemen-
tioned approaches depending on the type of the tumor and the
status of patients’ immune system. The most dangerous and dev-
astating outcome of the cancer is its ability to deplete NK cells and
other immune inflammatory cells. In this case, not only cancer
stem cells will be surviving but they will also remain poorly differ-
entiated which may establish a vicious cycle of tumor growth and
loss of immune effectors in the tumor microenvironment and in
the periphery. NK cell immunotherapy in these patients should be
highly beneficial.
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